Enzastaurin, a PKCβ inhibitor with in vitro IC50 for PKCα: 39 nM, PKCβ: 6 nM, PKCγ: 83 nM, PKCε: 110 nM, is one of the best-studied inhibitors in NSCLC [85]. This evidence concerns the gene PRKCB and non-small cell lung carcinoma.